Testing the SAPIEN X4 heart valve in people with severe aortic stenosis
Tests the SAPIEN X4 replacement heart valve in people with symptomatic severe aortic stenosis.
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- Christchurch, New ZealandSee the siteAlso in 3 other countries, 64 sites
- Trial code
- Registry title
- ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
- Status
- Recruiting
- People taking part
- 1,234 people, planned
- Started
- 20 Jun 2022
- Expected to end
- Jan 2037
- Type of study
- Interventional, 3 groups
- Treatments tested
- SAPIEN X4 THV
- SAPIEN X4S
- Record updated
- 24 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with severe, calcified narrowing of the aortic heart valve (aortic stenosis) that causes symptoms. They will get the SAPIEN X4 or X4S valve through a catheter.
- Sex
- All sexes can join.
- Disease stage
- Severe, calcified aortic stenosis. Heart failure symptoms of NYHA class II or higher. The size of the valve ring must fit the SAPIEN X4 valve.
- Earlier treatment
- People who already have a mechanical or tissue heart valve in any position cannot join. People who had any surgery or catheter procedure within 30 days before cannot join, unless it is part of the planned treatment of coronary artery disease. A pacemaker or ICD is allowed.
Main reasons for not taking part
- Aortic valve with one or two leaflets (unicuspid, bicuspid) or without calcium
- Left ventricular ejection fraction < 20%, or heart attack within 30 days
- Stroke or TIA within 90 days, or endocarditis within 180 days
- Kidney failure or being on dialysis or other kidney replacement therapy
- Pregnancy or breastfeeding, BMI > 50 kg/m2, or life expectancy < 24 months
The registry criteria, word for word
Show all 35 criteriaShow less
Who can take part
- Severe, calcific AS
- Native aortic annulus size suitable for SAPIEN X4 THV
- NYHA functional class ≥ II
- The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent
Who cannot take part
- Myocardial infarction within 30 days prior to the study procedure
- Subjects with planned concomitant ablation for atrial fibrillation
- Any surgical or transcatheter procedure within 30 days prior to the study procedure (unless part of planned strategy for treatment of CAD). Implantation of a permanent pacemaker or implantable cardioverter defibrillator (ICD) is not considered an exclusion
- Any planned surgical or transcatheter intervention to be performed within 30 days following the study procedure (unless part of planned strategy for treatment of CAD)
- Endocarditis within 180 days prior to the study procedure
- Stroke, transient ischemic attack or neurological signs and symptoms attributed to carotid or vertebrobasilar disease within 90 days prior to the study procedure
- Hemodynamic or respiratory instability requiring inotropic or mechanical support within 30 days prior to the study procedure
- Inability to tolerate or condition precluding treatment with antithrombotic therapy
- Absolute contraindications or allergy to iodinated contrast that cannot be adequately treated with premedication
- Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
- Participating in another investigational drug or device study that has not reached its primary endpoint
- Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
- Complex coronary artery disease (CAD) that cannot be optimally treated by percutaneous coronary intervention (PCI)
- Renal insufficiency and/or renal replacement therapy
- Hypercoagulable state or other condition that increases risk of thrombosis
- Left ventricular ejection fraction < 20%
- Anatomical characteristics that would preclude safe femoral placement of the introducer sheath or safe passage of the delivery system
- Aortic valve is unicuspid, bicuspid or non-calcified
- Pre-existing mechanical or bioprosthetic valve in any position
- Severe aortic regurgitation (> 3+)
- Severe mitral regurgitation (> 3+) or ≥ moderate mitral stenosis
- Need for mitral, tricuspid or pulmonic valve intervention within the next 12 months
- Left ventricular outflow tract calcification that would increase the risk of annular rupture or significant PVL after THV implantation
- Increased risk of coronary artery obstruction after THV implantation
- Hypertrophic cardiomyopathy with subvalvular obstruction
- Leukopenia, anemia, thrombocytopenia
- Subject refuses blood products
- BMI > 50 kg/m2
- Estimated life expectancy < 24 months
- Female who is pregnant or lactating
- Subject considered to be part of a vulnerable population
Where in New Zealand
Also in 3 other countries, 64 sites
- Christchurch HospitalChristchurch, New ZealandContact: Edwards THV Clinical AffairsNo longer taking part
About the trial
What the trial wants to find out
The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4/X4S Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS).
The 3 groups in the trial
- TAVR - Main CohortTreatment being tested
Subjects will undergo transcatheter aortic valve replacement (TAVR)
Treatment: SAPIEN X4 THV
- TAVR - Bicuspid RegistryTreatment being tested
Subjects with bicuspid aortic valve morphology will undergo TAVR
Treatment: SAPIEN X4 THV
- TAVR - X4S RegistryTreatment being tested
Subjects will undergo transcatheter aortic valve replacement (TAVR)
Treatment: SAPIEN X4S
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve
- Plain-language title
- Testing the SAPIEN X4 heart valve in people with severe aortic stenosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 24 September 2026